Get the Stockscreener App
1.16
3.33%
-0.04
Evogene Ltd stock is traded at $1.16, with a volume of 56,631.
It is down -3.33% in the last 24 hours and down -13.43% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
56,631
Relative Volume:
0.03
Market Cap:
$10.46M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-2.1887
EPS:
-0.53
Net Cash Flow:
$-22.36M
1W Performance:
-11.45%
1M Performance:
-13.43%
6M Performance:
-26.11%
1Y Performance:
-76.18%
1-Day Range:
$1.13
$1.20
1-Week Range:
$1.13
$1.32
52-Week Range:
$0.95
$4.86
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.16 | 10.46M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
What is the dividend policy of Evogene Ltd. stockFinancial News Planner For Beginners - jammulinksnews.com
What are the latest earnings results for Evogene Ltd.Earnings Report Alerts With Proven Results - jammulinksnews.com
Is Evogene Ltd. a growth stock or a value stockStock Market Ideas With Proven Results - jammulinksnews.com
What risks could impact Evogene Ltd. stock performanceConsistent Profit Pattern Recognition Tools Shared - metal.it
Evogene Schedules Second Quarter 2025 Financial Results Release - 富途牛牛
How does Evogene Ltd. compare to its industry peersPre Market Trend Scanner From AI Tools - jammulinksnews.com
Evogene Ltd. Company Revenue and Profit Trends: A Deep DiveExpert Verified Stock Trade Ideas Backed by Data - metal.it
What markets is EYEN expanding into Is Evogene Ltd. stock a good long term investment optionHigh-profit stock alerts - jammulinksnews.com
Is Evogene Ltd. stock overvalued or undervaluedDiscover undervalued stocks before they soar - jammulinksnews.com
How many analysts rate Evogene Ltd. as a “Buy”Invest smarter with actionable stock recommendations - jammulinksnews.com
What markets is Evogene Ltd. expanding into Is SBCF stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com
Should I hold or sell Evogene Ltd. stock in 2025Explosive market performance - jammulinksnews.com
Why is Evogene Ltd. stock attracting strong analyst attentionPhenomenal capital gains - jammulinksnews.com
Does Evogene Ltd. stock perform well during market downturnsCapitalize on market trends with confidence - jammulinksnews.com
Why Evogene Ltd. stock attracts strong analyst attentionFree Predictions - metal.it
Is Evogene Ltd. a good long term investmentRemarkable growth - PrintWeekIndia
Evogene Ltd. Stock Analysis and ForecastExplosive earning power - PrintWeekIndia
How Evogene Ltd. stock reacts to Fed policy changesRecord-setting profit potential - jammulinksnews.com
What drives Evogene Ltd. stock priceExceptional trading results - PrintWeekIndia
What analysts say about Evogene Ltd. stockRemarkably fast returns - jammulinksnews.com
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - global-agriculture.com
Evogene Updates Proxy Card for August 2025 Shareholder Meeting - The Globe and Mail
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):